Non-Steroidal Anti-inflammatory Drugs Market Size, Analysis, Trends, And Strategies 2024-2033

"The new report published by The Business Research Company, titled Non-Steroidal Anti-inflammatory Drugs Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the non-steroidal anti-inflammatory drugs market size has grown strongly in recent years. It will grow from $19.56 billion in 2023 to $20.93 billion in 2024 at a compound annual growth rate (CAGR) of 7.0%. The non-steroidal anti-inflammatory drugs market size is expected to see strong growth in the next few years. It will grow to $27.09 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=8023&type=smp

Rising Prevalence Of Chronic Pain To Drive Market Growth
The growing incidence of chronic pain is expected to propel the growth of the non-steroidal anti-inflammatory drugs market going forward. Chronic pain refers to discomfort that persists for more than six months. Non-steroidal anti-inflammatory drugs are used to heal injuries and treat chronic pain. For instance, in April 2022, according to the report of the CDC (Centers for Disease Control and Prevention), a US-based government agency, chronic pain was frequently caused by arthritis that affects millions of people in the US. Approximately one in four adults with arthritis among 15 million people are experiencing severe joint pain related to arthritis. Therefore, the growing incidence of chronic pain is driving the growth of the non-steroidal anti-inflammatory drugs market.

Product Innovations Transforming The Non-Steroidal Anti-Inflammatory Drugs Market
Product innovation is a key trend in the non-steroidal anti-inflammatory drugs market. Major companies operating in the non-steroidal anti-inflammatory drugs market are concentrating on creating new technology solutions. For instance, in May 2021, Ono and Seikagaku, a Japan-based company operating in non-steroidal anti-inflammatory drugs, launched JOYCLU, a 30 mg intra-articular injection. It is a formulation that uses Seikagaku's proprietary technology to chemically bind hyaluronic acid with diclofenac (an anti-inflammatory medication). It is intended to release diclofenac in the joint via hydrolysis, is licenced for the treatment of osteoarthritis, and is predicted to relieve symptoms after a four-week intra-articular injection. It is administered directly into the joint cavity as an injection, resulting in low systemic exposure to diclofenac and a low risk of a systemic adverse drug reaction. It is the first ethical drug in Japan with the indication of osteoarthritis of the hip joint among joint function improvement agents.

The non-steroidal anti-inflammatory drugs market covered in this report is segmented -

1) By Route of Administration: Oral, Topical, Other Route of Administration
2) By Disease Indication: Arthritis, Migraine, Ophthalmic Diseases, Other Disease Indications
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=8023&type=discount

Major companies operating in the non-steroidal anti-inflammatory drugs market report are Pfizer Inc., Bayer AG, Johnson & Johnson, Sun Pharmaceutical Industries Ltd., Assertio Therapeutics Inc., Iroko Pharmaceuticals Inc., Reckitt Benckiser Group plc, Perrigo Company plc, Hikma Pharmaceuticals Public Limited Company, Glenmark Pharmaceuticals Limited, Septodont, Aspen Pharmacare Holdings Limited, Sagent Pharmaceuticals Inc., Advanced Pharma Inc., Akorn Operating Company LLC, Alembic Pharmaceuticals Limited, Torrent Pharmaceuticals Limited, Lupin Limited, Cipla Limited, Zydus Cadila Healthcare Limited, Aurobindo Pharma Limited, Sanofi S.A., GlaxoSmithKline plc, Horizon Therapeutics plc, Zyla Life sciences, Novartis AG, Roche Holding AG, AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company

Contents of the report:
1. Executive Summary
2. Non-Steroidal Anti-inflammatory Drugs Market Report Structure
3. Non-Steroidal Anti-inflammatory Drugs Market Trends And Strategies
4. Non-Steroidal Anti-inflammatory Drugs Market - Macro Economic Scenario
5. Non-Steroidal Anti-inflammatory Drugs Market Size And Growth
…..
27. Non-Steroidal Anti-inflammatory Drugs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/non-steroidal-anti-inflammatory-drugs-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.